Subjects with a known or suspected alcohol or drug abuse which in the opinion of the investigator could interfere with the subject's proper completion of the protocol requirement.
History of life threatening asthma: Defined as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 6 months.
A lower respiratory tract infection within 7 days of the screening visit.
Concurrent diagnosis of chronic obstructive pulmonary disease (COPD) or other respiratory disorders including active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases.
History of hypersensitivity/intolerance to any components of the study inhalers (example, lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates participation will also be excluded.
Historical or current evidence of clinically significant or rapidly progressing or unstable cardiovascular, neurological, cardiovascular, neurological, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the analysis if the disease/condition exacerbated during the study.
Subjects who have ever received treatment with biological based therapy example, omalizumab, mepolizumab, for asthma.
Subjects who have received an investigational drug and/or medical device within 30 days of entry into this study (Screening), or within five drug half-lives of the investigational drug, whichever is longer.
A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, employee of the participating investigator, or any family member of a Propeller Health employee.

NCT03380429_exc_T2
Qualifier
life threatening
NCT03380429_exc_T3
Condition
asthma
NCT03380429_exc_T4
Condition
asthma episode
NCT03380429_exc_T5
Qualifier
required intubation
NCT03380429_exc_T6
Procedure
intubation
NCT03380429_exc_T7
Condition
hypercapnea
NCT03380429_exc_T8
Condition
respiratory arrest
NCT03380429_exc_T9
Condition
hypoxic seizures
NCT03380429_exc_T10
Temporal
within the last 6 months
NCT03380429_exc_T11
Scope
hypercapnea, respiratory arrest or hypoxic seizures
NCT03380429_exc_T12
Scope
asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 6 months
NCT03380429_exc_T13
Condition
lower respiratory tract infection
NCT03380429_exc_T14
Temporal
within 7 days of the screening visit
NCT03380429_exc_T15
Reference_point
screening visit
NCT03380429_exc_T16
Condition
chronic obstructive pulmonary disease (COPD)
NCT03380429_exc_T17
Qualifier
other
NCT03380429_exc_T18
Condition
respiratory disorders
NCT03380429_exc_T19
Qualifier
active
NCT03380429_exc_T20
Condition
tuberculosis
NCT03380429_exc_T21
Condition
lung cancer
NCT03380429_exc_T22
Condition
bronchiectasis
NCT03380429_exc_T23
Condition
sarcoidosis
NCT03380429_exc_T24
Condition
lung fibrosis
NCT03380429_exc_T25
Condition
pulmonary hypertension
NCT03380429_exc_T26
Condition
interstitial lung diseases
NCT03380429_exc_T27
Qualifier
other
NCT03380429_exc_T28
Qualifier
active
NCT03380429_exc_T29
Condition
pulmonary diseases
NCT03380429_exc_T30
Scope
chronic obstructive pulmonary disease (COPD) or other respiratory disorders
NCT03380429_exc_T31
Scope
active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
NCT03380429_exc_T32
Condition
hypersensitivity
NCT03380429_exc_T33
Condition
intolerance
NCT03380429_exc_T34
Drug
lactose
NCT03380429_exc_T35
Drug
magnesium stearate
NCT03380429_exc_T36
Drug
components of the study inhalers
NCT03380429_exc_T37
Scope
lactose, magnesium stearate
NCT03380429_exc_T38
Scope
hypersensitivity/intolerance
NCT03380429_exc_T39
Observation
history
NCT03380429_exc_T40
Qualifier
severe
NCT03380429_exc_T41
Drug
milk protein
NCT03380429_exc_T42
Condition
allergy
NCT03380429_exc_T44
Condition
contraindicates participation
NCT03380429_exc_T45
Condition
hematological abnormalities
NCT03380429_exc_T46
Qualifier
clinically significant
NCT03380429_exc_T47
Qualifier
rapidly progressing
NCT03380429_exc_T48
Condition
ovascular, neu malities that
NCT03380429_exc_T49
Qualifier
unstable
NCT03380429_exc_T50
Scope
clinically significant or rapidly progressing or unstable
NCT03380429_exc_T51
Condition
logical, car malities that
NCT03380429_exc_T52
Condition
ovascular, neu malities that
NCT03380429_exc_T53
Condition
logical, ren malities that
NCT03380429_exc_T54
Condition
, hep malities that
NCT03380429_exc_T55
Condition
ic, imm malities that
NCT03380429_exc_T56
Condition
ological, end malities that
NCT03380429_exc_T57
Condition
rine (inc malities that
NCT03380429_exc_T58
Qualifier
uncontrolled
NCT03380429_exc_T59
Condition
diabetes
NCT03380429_exc_T60
Condition
thyroid disease
NCT03380429_exc_T61
Scope
diabetes or thyroid disease
NCT03380429_exc_T62
Qualifier
uncontrolled
NCT03380429_exc_T63
Scope
cardiovascular, neurological, cardiovascular, neurological, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities
NCT03380429_exc_T64
Observation
Historical
NCT03380429_exc_T65
Temporal
current
NCT03380429_exc_T66
Scope
Historical or current
NCT03380429_exc_T68
Procedure
treatment
NCT03380429_exc_T69
Drug
omalizumab
NCT03380429_exc_T70
Drug
mepolizumab
NCT03380429_exc_T71
Drug
asthma
NCT03380429_exc_T72
Scope
omalizumab, mepolizumab, for asthma